Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC, its proprietary implant for repairing damaged knee cartilage, in Israel. The news, detailed in a press release from BioMedWire, marks a significant step in the company's global commercialization strategy and could signal upcoming revenue streams for the regenerative medicine sector.
GelrinC has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.
The deal matters because it provides Regentis with a commercial foothold in Israel while it continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The Israeli agreement supports Regentis' broader commercialization efforts in Europe and Israel, potentially accelerating adoption of its Gelrin platform technology based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.
For investors, the agreement offers a path to initial revenue in 2027, though the company notes that this content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. To view the full press release, visit https://ibn.fm/gk9yG.
BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries, along with article and editorial syndication to 5,000+ outlets. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
